GAMMA Investing LLC Has $90,000 Stake in Certara, Inc. (NASDAQ:CERT)

GAMMA Investing LLC lifted its position in shares of Certara, Inc. (NASDAQ:CERT) by 442.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,421 shares of the company’s stock after buying an additional 6,868 shares during the quarter. GAMMA Investing LLC’s holdings in Certara were worth $90,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. The Manufacturers Life Insurance Company raised its position in shares of Certara by 4.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company’s stock worth $317,000 after acquiring an additional 975 shares in the last quarter. Nicolet Advisory Services LLC lifted its stake in Certara by 6.6% in the third quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company’s stock valued at $273,000 after buying an additional 1,531 shares during the period. KBC Group NV boosted its holdings in shares of Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after buying an additional 1,584 shares in the last quarter. Blue Trust Inc. grew its position in shares of Certara by 112.3% during the 3rd quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock worth $46,000 after buying an additional 2,076 shares during the period. Finally, Everence Capital Management Inc. increased its stake in shares of Certara by 21.0% in the 3rd quarter. Everence Capital Management Inc. now owns 14,910 shares of the company’s stock valued at $175,000 after acquiring an additional 2,590 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

Certara Price Performance

CERT opened at $10.61 on Friday. The firm’s fifty day moving average price is $10.84 and its two-hundred day moving average price is $12.01. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of -53.05, a P/E/G ratio of 5.86 and a beta of 1.52. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara, Inc. has a 1 year low of $9.41 and a 1 year high of $19.87.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. The business had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.06 earnings per share. As a group, analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on CERT shares. Robert W. Baird reduced their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Barclays dropped their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. Finally, UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Friday, September 27th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $15.92.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.